SecBot SecBot
SECBOTREPLAY Home › Report › VNDA

VNDA · Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in…

Vanda Pharmaceuticals Inc. · 8-K filed May 6, 2026 at 16:06 ET

At the news

MIXEDIMPACT 6/10

8-K filed May 6, 2026 at 16:06 ET

Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in line with modest growth, but EPS of -$0.82 missed the Street consensus of -$0.53 by 55% as net loss widened to $48.6M. Positives include 26% Fanapt growth, FDA approval of BYSANTI, NEREUS launch, and raised FY2026 revenue guidance to $240-290M (from $230-260M). The mixed results balance a significant EPS miss against strong pipeline and commercial catalysts.

  • Q1 2026 total revenue $51.7M, up 3% YoY from $50.0M
  • Fanapt net product sales $29.6M, up 26% YoY
  • GAAP diluted EPS -$0.82 vs consensus -$0.53 (miss of 54.7%)
  • Net loss $48.6M vs $29.5M in Q1 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access